
Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.
Supplements and Featured Publications
Scott Plotkin, MD, reviews data from a phase II study on brigatinib, a multi tyrosine kinase inhibitor, across various tumor types in patients with NF2-related schwannomatosis.






